|
Market Closed -
Nasdaq
16:00:00 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 514.65 USD | +2.53% |
|
+1.51% | +13.52% |
| 10-15 | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| 10-09 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Other Pharmaceuticals | +2.53% | +1.51% | +13.52% | +23.47% | +177.57% | 127B |  | |  |
- Stock Market
- Stocks
- VRTX Stock
- Charts Vertex Pharmaceuticals Incorporated
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
